Congenital chylothorax treated with oral sildenafil: a case report and review of the literature.
Congenital chylothorax (CC) can result from a congenital malformation or an acquired obstruction or disruption of the thoracic duct. Recently, oral administration of the phosphodiesterase-5 inhibitor, sildenafil, was reported to be effective in resolving non-pulmonary lymphatic malformations in infants and young children. We report a case of CC in a late preterm infant with congenital pulmonary lymphangiectasia where octreotide was not effective, but management with oral sildenafil was successful.
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA.
D T
DT
Malleske
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA.
B A
BA
Yoder
D002916:Chylothorax / Q000151:congenital* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D008168:Lung / Q000000981:diagnostic imaging; D008171:Lung Diseases / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy; D008200:Lymphangiectasis / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D000068677:Sildenafil Citrate / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed
D058986:Phosphodiesterase 5 Inhibitors; D000068677:Sildenafil Citrate